J&J’s Baby powder tested in India and Bangladesh
December 21, 2018Medical Communications Bangladesh, Cancer, India, J&J, JJ, asbestos
Bangladeshi authorities will collect and test samples of Johnson & Johnson’s baby powders for traces of cancer causing asbestos, after …
Top Ten most popular articles on Pharmafile.com this week!
December 21, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Eisai, Eli Lilly, Novartis, Teva, Tilray, brexit, celltrion, pharma, top 10
Deals dominated this week as GSK and Pfizer announced that they would combine their consumer healthcare units in a collaboration …
Merck KGaA hands over CAR-T therapy business to Intrexon in deal worth $175 million
December 20, 2018Business Services, Medical Communications, Sales and Marketing CAR T, CAR-T, Cancer, Germany, Intrexon, Merck KGaA, darmstadt, oncology
German pharma firm Merck KGaA has agreed to hand over its CAR-T therapy business to US company Intrexon in a …
Novartis Oncology CEO steps down after 11 months
December 20, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Liz Barret, the CEO of Swiss firm Novartis Oncology has said that she is standing down after being in the …
KCL researchers find link between overactive immune system and Chronic Fatigue Syndrome/ ME
December 20, 2018Research and Development CFS, KCL, King's College London, Kings College London, ME
Chronic fatigue syndrome (CFS) or Myalgic encephalomyelitis (ME) may be caused by an overactive immune system, according to researchers at …
Medics in Vanuatu transport vaccines via drone
December 20, 2018Business Services, Medical Communications Transport, Vanuata, drone, supply chain, vaccines
Medics in the remote archipelago of Vanuatu have begun to deliver vaccines using a commercial drone. The logistical success marks …
Gilead and Scholar Rock collaborate on fibrosis in deal worth more than $80m
December 20, 2018Business Services, Research and Development Califonia, Gilead, Scholar Rock, USA, fibrosis
California-based antiviral drugs specialist Gilead Sciences has entered into a strategic partnership with Cambridge, Massachusetts-based biotech Scholar Rock as part …
AstraZeneca scores hat trick in ovarian cancer and anaemia clinical trials
December 20, 2018Research and Development AstraZeneca, anaemia, oncology, ovarian cancer, pharma
Anglo-Swedish multinational AstraZeneca has revealed that its ovarian cancer drug (Lynparza) and anaemia treatment (Roxadustat) have met their goals in …
Taisho Pharma to buy Bristol-Myers Squibb’s consumer health business in deal worth $1.6 bn
December 19, 2018Business Services BMS, Japan, M&A, MA, Taisho, deal
Japanese company Taisho Pharmaceuticals has offered Bristol-Myers Squibb $1.6 billion for its UPSA consumer health business. With more than a …
NICE recommends Lenvima as alternative first-line therapy for advanced liver cancer
December 19, 2018Research and Development, Sales and Marketing Lenvima, NICE, UK, liver cancer, pharma
UK drug watchdog NICE has revealed that it has recommended Eisai’s Lenvima (lenvatinib) for use on the NHS in England …
China becomes first country to approve roxadustat in chronic kidney disease
December 19, 2018Research and Development, Sales and Marketing AstraZeneca, China, chronic kidney disease, pharma
AstraZeneca has announced that its partner Fibrogen has secured the first national approval for its hypoxia-inducible factor prolyl hydroxylase inhibitor …
Indian authorities seize J&J Baby Powder in response to Reuters report
December 19, 2018Research and Development Cancer, India, J&J, JJ, asbestos, baby powder, regulation
Indian authorities have seized samples of Johnson & Johnson’s Baby Powder from a factory in Baddi in Northern India, after …
GSK and Pfizer combine healthcare units in multibillion dollar deal
December 19, 2018Research and Development GSK, OTC, Pfizer, healthcare, merger
American multinational Pfizer and British firm GlaxoSmithKline are set to combine their consumer healthcare units in a venture worth billions. …
Novartis inks deal with Canadian cannabis firm Tilray
December 18, 2018Research and Development Marijuana, Novartis, Sandoz, Tilray, cannabis
Shares in Canadian cannabis company Tilray jumped by more than 11% today after the British Columbia-based firm announced its entry …
Pharma in 2018: Looking back, looking forward
December 18, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2018, Alligator Bioscience, Eisai, Gilead, Mundipharma, pharma
2018 has been a year characterised by uncertainty, but also significant leaps in research, access, and industry deals. With 2019 …
NHS spends £26 million on consultancy
December 18, 2018Manufacturing and Production BMA, Consultancy, Jobs, NHS, health
Private consultancy firms were paid at least £26 million as part of a reorganisation of the NHS, in what has …
Celltrion and Teva’s Herceptin biosimilar secures FDA approval in breast cancer
December 18, 2018Manufacturing and Production, Sales and Marketing Herceptin, Herzuma, Teva, celltrion, pharma
Israeli and South Korean-based drug makers Teva and Celltrion are set to move in on the market share occupied by …
Eli Lilly’s Taltz shows superiority over AbbVie’s Humira
December 18, 2018Manufacturing and Production Eli Lilly, Humira, Taltz, arthritis, immune system
A study has found that Eli Lilly’s Taltz (ixekizumab) met the primary, and all secondary endpoints, in patients with active …
J&J announces $5bn share repurchase
December 18, 2018Manufacturing and Production J&J, JJ, Shares, asbestos, baby powder, reuters, scandal
New Jersey-based pharma firm Johnson & Johnson plans to buy back $5 billion in shares after news agency Reuters released …
The Autumn 2018 edition of Pharmafile is available to read online now!
December 18, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing immunology, infectious diseases, pharma, pharmafile, rare diseases
The Autumn 2018 edition of Pharmafile, our long-running bi-annual guide to the latest trends, projections and thought leadership positions in …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
